Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
TGF-β–induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis
Clara Dees, … , Georg Schett, Jörg H.W. Distler
Clara Dees, … , Georg Schett, Jörg H.W. Distler
Published January 28, 2020
Citation Information: J Clin Invest. 2020;130(5):2347-2363. https://doi.org/10.1172/JCI122462.
View: Text | PDF
Research Article Cell biology Immunology Article has an altmetric score of 10

TGF-β–induced epigenetic deregulation of SOCS3 facilitates STAT3 signaling to promote fibrosis

  • Text
  • PDF
Abstract

Fibroblasts are key effector cells in tissue remodeling. They remain persistently activated in fibrotic diseases, resulting in progressive deposition of extracellular matrix. Although fibroblast activation may be initiated by external factors, prolonged activation can induce an “autonomous,” self-maintaining profibrotic phenotype in fibroblasts. Accumulating evidence suggests that epigenetic alterations play a central role in establishing this persistently activated pathologic phenotype of fibroblasts. We demonstrated that in fibrotic skin of patients with systemic sclerosis (SSc), a prototypical idiopathic fibrotic disease, TGF-β induced the expression of DNA methyltransferase 3A (DNMT3A) and DNMT1 in fibroblasts in a SMAD-dependent manner to silence the expression of suppressor of cytokine signaling 3 (SOCS3) by promoter hypermethylation. Downregulation of SOCS3 facilitated activation of STAT3 to promote fibroblast-to-myofibroblast transition, collagen release, and fibrosis in vitro and in vivo. Reestablishment of the epigenetic control of STAT3 signaling by genetic or pharmacological inactivation of DNMT3A reversed the activated phenotype of SSc fibroblasts in tissue culture, inhibited TGF-β–dependent fibroblast activation, and ameliorated experimental fibrosis in murine models. These findings identify a pathway of epigenetic imprinting of fibroblasts in fibrotic disease with translational implications for the development of targeted therapies in fibrotic diseases.

Authors

Clara Dees, Sebastian Pötter, Yun Zhang, Christina Bergmann, Xiang Zhou, Markus Luber, Thomas Wohlfahrt, Emmanuel Karouzakis, Andreas Ramming, Kolja Gelse, Akihiko Yoshimura, Rudolf Jaenisch, Oliver Distler, Georg Schett, Jörg H.W. Distler

×

Figure 3

Dysregulated expression of DNMT3A.

Options: View larger image (or click on image) Download as PowerPoint
Dysregulated expression of DNMT3A.
(A) mRNA and protein levels of DNMT1,...
(A) mRNA and protein levels of DNMT1, DNMT3A, and DNMT3B upon chronic stimulation with TGF-β in normal dermal fibroblasts. n = 5 fibroblast lines from different donors with 2 technical replicates each for qPCR; n = 3 fibroblast lines from different donors with 3 technical replicates each for Western blot. (B) Activity of DNMTs upon chronic stimulation with TGF-β. n = 4 fibroblast lines from different donors with 2 technical replicates each. (C) mRNA and protein levels of SOCS3 and DNMT3A upon knockdown of DNMT3A in TGF-β–stimulated normal fibroblasts. n = 12 fibroblast lines from different donors for qPCR with 2 technical replicates each; n = 3 fibroblast lines from different donors for Western blot with 3 technical replicates each. (D) Expression of SOCS3 upon knockdown of DNMT1 or DNMT3A in SSc fibroblasts. n = 4 fibroblast lines from different donors with 2 technical replicates each. (E and F) mRNA and protein levels of DNMT1, DNMT3A, and DNMT3B in (E) human skin and (F) human cultured fibroblasts. n = 6 fibroblast lines or skin samples from different donors for qPCR with 2 technical replicates each; n = 4 fibroblast lines or skin samples from different donors for Western blot with 3 technical replicates each. Data are depicted as the median with interquartile range. Each dot represents an individual result. One-way ANOVA with Tukey’s range test as post hoc analysis (A–D) or Mann-Whitney U test (E and F) was used for statistical analyses. 0.05 > *P ≥ 0.01; 0.01 > **P ≥ 0.001; ***P < 0.001.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Posted by 18 X users
74 readers on Mendeley
See more details